COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,609 Articles (22,913 medRxiv, 8,696 bioRxiv)

Most recent first Previous |  Page 1115: Articles 11141-11150  | Next

Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction
Rouhani, S. J., Trujillo, J. A., Pyzer, A. R., Yu, J., Fessler, J. L., Cabanov, A., Higgs, E. F., Cron, K. R., Zha, Y., Lu, Y., Bloodworth, J. C., Abasiyanik, M. F., Okrah, S., Flood, B. A., Hatogai, K., Leung, M. Y., Pezeshk, A., Kozloff, L., Reschke, R., Strohbehn, G. W., Chervin, C. S., Kumar, M., Schrantz, S., Madariaga, M. L., Beavis, K. G., Yeo, K.-T. J., Sweis, R., Segal, J., Tay, S., Izumchenko, E., Mueller, J., Chen, L. S., Gajewski, T. F.
10.1101/2021.12.09.21266492 — Posted: 2021-12-11
Analytical evaluation of thirty-two SARS-CoV-2 lateral flow antigen tests demonstrates sensitivity remains with the SARS-CoV-2 Gamma lineage.
Kontogianni, N., Bengey, D., Wooding, D., Buist, K., Greenland-Bews, C., Williams, C. T., de Vos, M., Escadafal, C., Adams, E. R., Edwards, T., Cubas Atienzar, A. I.
10.1101/2021.12.08.21267455 — Posted: 2021-12-11
Predicted Symptomatic Effectiveness of Pfizer-BioNTech BNT162b2 Vaccine Against Omicron Variant of SARS-CoV-2
Volkov, O.
10.1101/2021.12.09.21267556 — Posted: 2021-12-11
Estimating Active Cases of COVID-19
Alvarez, J., Baquero, C., Cabana, E., Prakash Champati, J., Fernandez Anta, A., Frey, D., Garcia-Agundez Garcia, A., Georgiou, C., Goessens, M., Hernandez, H., Lillo, R., Menezes, R., Moreno, R., Nicolaou, N., Ojo, O., Ortega, A., Rausell, E., Rufino, J., Stavrakis, E., Jeevan, G., Glorioso, C.
10.1101/2021.12.09.21267355 — Posted: 2021-12-10
Stranded abroad during the COVID-19 pandemic: examining the psychological and financial impact of border restrictions
McDermid, P., Craig, A., Sheel, M., Blazek, K., Talty, S., Seale, H.
10.1101/2021.12.08.21267218 — Posted: 2021-12-09
Risk of hospitalization and mortality after breakthrough SARS-CoV-2 infection by vaccine type and previous SARS-CoV-2 infection utilizing medical claims data
Kshirsagar, M., Mukherjee, S., Nasir, M., Becker, N., Lavista Ferres, J. M., Richardson, B.
10.1101/2021.12.08.21267483 — Posted: 2021-12-09
Omicron strain spreads with the doubling time of 3.2-3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant
Grabowski, F., Kochanczyk, M., Lipniacki, T.
10.1101/2021.12.08.21267494 — Posted: 2021-12-09
Population Optimally Immunized after Accounting for Type-Specific COVID-19 Vaccine Waning Intervals: State-Level Prevalence and Trends
Pathak, E. B., Salemi, J. L.
10.1101/2021.12.09.21267295 — Posted: 2021-12-09
The unequal impact of the COVID-19 pandemic on life expectancy across Chile
Mena, G. E., Aburto, J. M.
10.1101/2021.12.08.21267475 — Posted: 2021-12-09
Surveillance of COVID-19 vaccine effectiveness - a real-time case-control study in southern Sweden
Bjork, J., Bonander, C., Moghaddassi, M., Rasmussen, M., Malmqvist, U., Kahn, F., Inghammar, M.
10.1101/2021.12.09.21267515 — Posted: 2021-12-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).